Key Takeaways Pfizer will report Q3 results on Nov. 4, with investors watching the performance of key non-oncology drugs.Eliquis sales likely climbed, driven by higher demand trends globally.Abrysvo demand was likely limited by RSV guidance, while Xeljanz and Enbrel sales likely declined.Pfizer (PFE) is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which account for more than 25% of the company’s total revenues. Pfizer’s key oncology drugs are Ibra ...